Triamine derivative
US8088796B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2006 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | Apr 28, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1):wherein R1 and R2 each independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group; Q1 represents a saturated or unsaturated bicyclic or tricyclic fused hydrocarbon group which may be substituted, a saturated or unsaturated bicyclic or tricyclic fused heterocyclic group which may be substituted, or the like; Q2 represents a single bond, a straight-chained or branched alkylene group having 1 to 6 carbon atoms, a straight-chained or branched alkenylene group having 2 to 6 carbon atoms, or the like; R3 and R4 each represent an alkyl group, or the like; m and n each represent an integer from 0 to 3; Q4 represents an aryl group; and T0 and T1 each represent a carbonyl group or the like, and a medicine containing the compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.